Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585999 · ClinicalTrials.gov registry record · NA
The Pharmacokinetics of 12 Week Continuous Patch Use
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02585999 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT02585999, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12 weeks of continuous contraceptive patch use. The secondary objective is assessing the the norelgestromin (NGMN) levels over the 12 weeks of continuous contraceptive patch use.
Interventions
- DEVICE Xulane Contraceptive Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02585999
The ClinicalTrials.gov registry entry for NCT02585999 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xulane Contraceptive Patch is the first listed.
NCT02585999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02585999 about?
NCT02585999 is a clinical study titled "The Pharmacokinetics of 12 Week Continuous Patch Use". Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12 weeks of continuous contraceptive ...
What is the current status of trial NCT02585999?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02585999?
The interventions under investigation include: Xulane Contraceptive Patch (DEVICE).
Who is sponsoring clinical trial NCT02585999?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.